文献速递消化、代谢与肾脏急症

阿司匹林对健康老年人脓毒症相关死亡的影响(ANTISEPSIS):随机双盲安慰剂对照一级预防试验

Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial.
PubMed 文献 · Lancet Respir Med · 2020-09-17
一句话结论在社区居住的70岁及以上健康老年人中,每日低剂量阿司匹林100 mg未减少脓毒症相关死亡(HR 1.08,95%CI 0.82-1.43;p=0.57)。

ANTISEPSIS是ASPREE试验的亚研究,纳入澳大利亚队列中16703名70岁及以上、无重大疾病的社区居住老年人,按1:1随机分配至每日阿司匹林100 mg或安慰剂,中位随访4.6年(IQR 3.6-5.6)。共发生203例脓毒症相关死亡,阿司匹林组与安慰剂组脓毒症相关死亡发生率相似(HR 1.08,95%CI 0.82-1.43;p=0.57)。作者认为每日低剂量阿司匹林未减少社区居住老年人的脓毒症相关死亡,研究结果不支持将阿司匹林作为该人群减少脓毒症负担的一级预防策略。

要点

  • 在70岁及以上无重大疾病的社区居住老年人中,每日阿司匹林100 mg未减少脓毒症相关死亡(HR 1.08,95%CI 0.82-1.43;p=0.57)。
  • 共203例死亡被认为与脓毒症相关,两组脓毒症相关死亡发生率相似。
  • 作者认为该结果不支持将阿司匹林作为该人群减少脓毒症负担的一级预防策略。
  • 阿司匹林组8322人(49.8%),安慰剂组8381人(50.2%),中位随访4.6年(IQR 3.6-5.6)。

适用人群与场景

  • 纳入标准:年龄至少70岁、无重大疾病的社区居住老年人;ANTISEPSIS为ASPREE试验的亚研究,仅纳入澳大利亚队列。
  • 排除人群:原文未报告具体排除标准;研究对象为无重大疾病的社区居住老年人,非急诊或ICU住院患者。

处置流程与药物剂量

  • 干预:阿司匹林100 mg每日口服,与安慰剂比较;用于社区居住的70岁及以上无重大疾病老年人一级预防。

研究设计与关键结果

  • 研究设计:ANTISEPSIS为ASPREE随机对照一级预防试验的亚研究,随机、双盲、安慰剂对照,纳入澳大利亚队列;2010年3月10日至2014年12月24日期间,20288人接受资格评估,16703名70岁及以上参与者入选并随访,中位随访4.6年(IQR 3.6-5.6);阿司匹林组8322人(49.8%),安慰剂组8381人(50.2%)。
  • 主要终点:203例死亡被认为与脓毒症相关;单变量分析显示两组脓毒症相关死亡发生率相似(阿司匹林 vs 安慰剂 HR 1.08,95%CI 0.82-1.43;p=0.57)。
  • 不良事件:原文指出不良事件已在ASPREE试验中报告。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照一级预防试验的亚研究(ANTISEPSIS,ASPREE亚研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为:每日低剂量阿司匹林未减少社区居住老年人的脓毒症相关死亡,研究结果不支持将阿司匹林作为该人群减少脓毒症负担的一级预防策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a serious global health issue and a major cause of death and disability. The availability of a simple, community-based preventive strategy could substantially reduce the burden of sepsis. We aimed to establish whether low-dose aspirin reduced deaths or hospital admissions associated with sepsis in older people.

METHODS: ANTISEPSIS was a substudy of ASPREE (a randomised controlled primary prevention trial of low-dose aspirin [100 mg per day] compared with placebo in community dwelling older adults conducted in Australia and the USA), with the Australian cohort included in the ANTISEPSIS substudy. Inclusion criteria were participants aged at least 70 years who did not have major illnesses. Participants were block randomised (1:1) via a centralised web portal and stratified by general practice and age. Participants, investigators, and staff were masked to the intervention. Teams of clinical specialist investigators assessed potential sepsis events to establish if they satisfied the primary endpoint of death associated with sepsis. The analyses were by intention-to-treat with univariate survival analysis methods, the log-rank test, and Cox proportional hazards regression. This study is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000349741.

RESULTS: Between March 10, 2010, and Dec 24, 2014, of 20 288 individuals assessed for eligibility, 16 703 participants aged 70 years and older at trial entry were enrolled and followed up for a median of 4·6 years (IQR 3·6-5·6). 8322 (49·8%) participants were assigned to receive aspirin and 8381 (50·2%) to placebo. 203 deaths were considered to be associated with sepsis. Univariate analysis showed similar rates of death associated with sepsis in the two study groups (hazard ratio for aspirin vs placebo 1·08, 95% CI 0·82-1·43; p=0·57). Adverse events were previously reported in the ASPREE trial.

INTERPRETATION: Daily low-dose aspirin treatment did not reduce deaths associated with sepsis in community dwelling older adults. Our findings do not support the use of aspirin as a primary prevention strategy to reduce the burden of sepsis in this population.

FUNDING: National Health and Medical Research Council of Australia, National Institutes of Health, Monash University.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Eisen DP, Leder K, Woods RL, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial. Lancet Respir Med. 2020. PMID: 32950072. doi:10.1016/S2213-2600(20)30411-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。